GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Joinn Laboratories (China) Co Ltd (SHSE:603127) » Definitions » Cash Flow from Operations

Joinn Laboratories (China) Co (SHSE:603127) Cash Flow from Operations : ¥756 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Joinn Laboratories (China) Co Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Mar. 2024, Joinn Laboratories (China) Co's Net Income From Continuing Operations was ¥-273 Mil. Its Depreciation, Depletion and Amortization was ¥0 Mil. Its Change In Working Capital was ¥0 Mil. Its cash flow from deferred tax was ¥0 Mil. Its Cash from Discontinued Operating Activities was ¥0 Mil. Its Asset Impairment Charge was ¥0 Mil. Its Stock Based Compensation was ¥0 Mil. And its Cash Flow from Others was ¥393 Mil. In all, Joinn Laboratories (China) Co's Cash Flow from Operations for the three months ended in Mar. 2024 was ¥120 Mil.


Joinn Laboratories (China) Co Cash Flow from Operations Historical Data

The historical data trend for Joinn Laboratories (China) Co's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Joinn Laboratories (China) Co Cash Flow from Operations Chart

Joinn Laboratories (China) Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only 148.09 428.39 685.66 971.07 622.88

Joinn Laboratories (China) Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.67 259.88 202.23 174.44 119.95

Joinn Laboratories (China) Co Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Joinn Laboratories (China) Co's Cash Flow from Operations for the fiscal year that ended in Dec. 2023 is calculated as:

Joinn Laboratories (China) Co's Cash Flow from Operations for the quarter that ended in Mar. 2024 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥756 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Joinn Laboratories (China) Co  (SHSE:603127) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Joinn Laboratories (China) Co's net income from continuing operations for the three months ended in Mar. 2024 was ¥-273 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Joinn Laboratories (China) Co's depreciation, depletion and amortization for the three months ended in Mar. 2024 was ¥0 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Joinn Laboratories (China) Co's change in working capital for the three months ended in Mar. 2024 was ¥0 Mil. It means Joinn Laboratories (China) Co's working capital {id_Q12} from Dec. 2023 to Mar. 2024 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Joinn Laboratories (China) Co's cash flow from deferred tax for the three months ended in Mar. 2024 was ¥0 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Joinn Laboratories (China) Co's cash from discontinued operating Activities for the three months ended in Mar. 2024 was ¥0 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Joinn Laboratories (China) Co's asset impairment charge for the three months ended in Mar. 2024 was ¥0 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Joinn Laboratories (China) Co's stock based compensation for the three months ended in Mar. 2024 was ¥0 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Joinn Laboratories (China) Co's cash flow from others for the three months ended in Mar. 2024 was ¥393 Mil.


Joinn Laboratories (China) Co Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Joinn Laboratories (China) Co's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Joinn Laboratories (China) Co (SHSE:603127) Business Description

Traded in Other Exchanges
Address
A5 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing, CHN, 100176
Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non- Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.
Executives
Yao Da Lin Director
Sun Yun Xia Director
Zuo Cong Lin Director
Gao Da Peng Director
Li Ye Supervisors
Gu Xiao Lei Director
Feng Yu Xia Director
Gu Jing Liang senior management
Yu Ai Shui senior management
Yin Li Li Supervisors
Sun Hui Ye Supervisors
Gu Mei Fang Director

Joinn Laboratories (China) Co (SHSE:603127) Headlines

No Headlines